Walgreens Boots Alliance soar 19% on Q1 results beat, upbeat guidance

Published 10/01/2025, 11:12 pm
Updated 11/01/2025, 01:42 am
© Reuters.
WBA
-

Walgreens Boots Alliance (NASDAQ:WBA) shares surged 19% on Friday after the pharmacy retailer reported first-quarter earnings and revenue above analyst expectations, and delivered an upbeat annual forecast.

The company reported earnings per share (EPS) of $0.51, topping the consensus estimates of $0.39. Revenue for the period reached $39.46 billion, also above the projected $37.35 billion.

In the US Retail Pharmacy segment, sales rose 6.6% year-over-year to $30.87 billion, surpassing the $29.16 billion estimate.

US Healthcare sales grew 12% year-over-year to $2.17 billion, ahead of the $2.09 billion forecast.

International sales increased 10% year-over-year, reaching $6.43 billion and outperforming the $5.9 billion projection.

Walgreens reported a quarterly adjusted gross margin of 17.3%, slightly below the prior year's 18.7% and missing the estimated 17.5%.

"Our first quarter results reflect our disciplined execution against our 2025 priorities: stabilizing the retail pharmacy by optimizing our footprint, controlling operating costs, improving cash flow and continuing to address reimbursement models,” said Tim Wentworth CEO of Walgreens Boots Alliance.

“While our turnaround will take time, our early progress reinforces our belief in a sustainable, retail pharmacy-led operating model."

For fiscal 2025, Walgreens projects EPS in the range of $1.40 to $1.80, compared to the analyst consensus of $1.53.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.